Ai In Medical Imaging MarketSize, Share & Industry Analysis, 2026-2034By ProductBy End UseBy ApplicationBy Ai TechnologyBy Component

Artificial intelligence in medical imaging covers software and integrated hardware that applies machine learning, most often deep learning and computer vision, to acquire, reconstruct, triage or interpret diagnostic images such as CT, MRI, ultrasound and optical coherence tomography scans. Buyers include hospitals and imaging centers seeking faster read times and fewer missed findings, imaging equipment makers embedding algorithms into new scanners, and pharmaceutical or biotechnology sponsors using image analysis in clinical trials. The category spans standalone diagnostic-support software, cloud-hosted image-analysis platforms and AI modules bundled directly into scanner consoles.

USD 1.85 billion of revenue was recorded in the global ai in medical imaging market in 2025. By 2034 the figure reaches USD 19.58 billion, a compound annual growth rate of 30% through the forecast period, along a series that runs USD 0.34 billion in 2020, USD 1.32 billion in 2024, USD 2.4 billion in 2026 and USD 6.85 billion in 2030.

Composition changes more than the total does. Optical Coherence Tomography Devices, at 35.8%, outgrows MRI Systems at 27.8%, and its share moves from 8% to 12%. CT Scanners stays the largest line throughout, at USD 0.592 billion in 2025 and USD 5.482 billion in 2034. Ultrasound Scanners and Optical Coherence Tomography Devices take share over the period; CT Scanners, MRI Systems and Others give it up while still growing in absolute terms.

The end use split puts Hospital and healthcare providers first, at USD 1.017 billion and 55% of revenue in 2025, rising to USD 9.79 billion and 50% in 2034. Healthcare payers grows faster at 33.3% against 28.6%, moving from 12% of revenue to 15% by 2034. It cuts the same total as the product axis from a different commercial angle, so revenue does not add across the two.

USD 0.833 billion of 2025 revenue is generated in North America, 45% of the global total and the largest regional share; it reaches USD 7.44 billion by 2034. Europe is next at 24% and USD 0.444 billion, and Middle East and Africa last at 4%. Share shifts toward Asia Pacific and Latin America over the forecast period, so the regional split repays a close reading.

The 2025 total is a triangulation of published figures and category proxies, short of a directly sourced total. Segment, regional and country splits are estimated on the same basis, which bounds the precision of the figures above. Coverage runs to five regions, five product lines and five segmentation axes across a fifteen-year window.

• Revenue grows from USD 1.85 billion in 2025 to USD 19.58 billion in 2034, a compound annual rate of 30%, having reached USD 1.32 billion in 2024 from USD 0.34 billion in 2020.
• 32% of 2025 revenue sits in CT Scanners (USD 0.592 billion) and it remains the largest product line in 2034 at USD 5.482 billion and 28%.
• At 35.8%, Optical Coherence Tomography Devices grows faster than any other product line, moving from USD 0.148 billion and 8% of revenue in 2025 to USD 2.35 billion and 12% in 2034.
• Scenario range for 2034 runs from USD 16.643 billion in the bear case to USD 22.517 billion in the bull case, against a base-case USD 19.58 billion, the spread a plan built on this forecast has to absorb.
• The largest region is North America, generating USD 0.833 billion in 2025 (45% of the global total) and USD 7.44 billion by 2034, ahead of Europe at 24%.
• 85% of North America's base-year revenue comes from the United States alone: USD 0.708 billion in 2025, rising to USD 6.324 billion by 2034, which is why it is that region's worked example.
• Fifteen years are reported, 2020 to 2034 with 2025 as the base: revenue, share and growth rate per line, per axis and per region, not as a single blended series.

Read across the forecast period, the global ai in medical imaging market shows movement in three places: product composition, regional weight, and the 30% rate applied to the whole.

Not one of them points downward. Growth is everywhere in absolute terms, and the interest is entirely in where it lands.

Optical Coherence Tomography Devices outpaces MRI Systems. Optical Coherence Tomography Devices grows at 35.8% across 2026-2034 against 27.8% for MRI Systems, the widest spread on the product axis. Optical Coherence Tomography Devices takes its share of revenue from 8% to 12% while MRI Systems gives up ground, from 28% to 24%. In absolute terms Optical Coherence Tomography Devices rises from USD 0.148 billion to USD 2.35 billion, while MRI Systems rises from USD 0.518 billion to USD 4.699 billion. Both grow; the gap is wide enough to reshape the mix inside a single forecast window.

Growth concentrates in Asia Pacific and Latin America. Asia Pacific moves from 22% of revenue in 2025 to 30% in 2034, worth USD 0.407 billion rising to USD 5.874 billion; Latin America moves from 5% of revenue in 2025 to 6% in 2034, worth USD 0.093 billion rising to USD 1.175 billion. Share moves off the others in turn: North America at 45% moving to 38%, Europe at 24% moving to 22%, Middle East and Africa at 4% moving to 4%, each still growing in revenue terms. Revenue added in this market is therefore concentrating geographically instead of spreading evenly, and a participant weighted toward a share-losing region grows more slowly than the market even while its own revenue climbs.

The series never breaks trajectory. The market moves through USD 0.34 billion in 2020, USD 1.32 billion in 2024, USD 1.85 billion in 2025, USD 2.4 billion in 2026, USD 6.85 billion in 2030 and USD 19.58 billion in 2034. The forecast rate of 30% sits against 40.3% over the historical period, so the projection extends an observed trend instead of proposing a new one. The risk in the number sits in the mix assumptions, not in whether the market grows at all, which is where the product and regional sections come in.

Optical Coherence Tomography Devices carries the market's growth rate

Growth in the global ai in medical imaging market comes from three measurable sources over 2026-2034: the market's own compounding at 30%, the share gained by faster-growing product lines, and expansion in the regions taking a larger part of global revenue.

The bear case and what drives it

Where the forecast could be beaten

The total depends on a single line

North America holds 45% of the global ai in medical imaging market in 2025, worth USD 0.833 billion with USD 7.44 billion projected for 2034. It is a dominant region on this axis, first by revenue throughout the period.

Share settles at 38% in 2034, though revenue still rises throughout; the shift is in the region's weight against faster-growing ones, which is not the same as weakening demand.

CT Scanners leads here as it does globally, at 32% of 2025 revenue, and Optical Coherence Tomography Devices again grows fastest at 35.8%. Revenue for North America is broken out by every segmentation axis and by country in the full report.

The United States is the largest market within North America, generating USD 0.708 billion in 2025 and projected to reach USD 6.324 billion by 2034. Because it is 85% of the region in the base year, North America's totals move with this one country instead of a spread of them. Against regional totals of USD 0.833 billion in 2025 and USD 7.44 billion in 2034, it is the country the full report breaks out in detail.

Demand in the United States follows the product mix reported at global level: CT Scanners is the largest line at 32% of 2025 revenue, moving to 28% by 2034, while Optical Coherence Tomography Devices grows fastest at 35.8% and takes its share from 8% to 12%. Its 85% weight in North America means those movements carry straight into the regional totals. Revenue by product for the United States is reported separately in the full report.

In the United States, AI-enabled medical imaging software is regulated by the Food and Drug Administration as a medical device, specifically as Software as a Medical Device under the Federal Food, Drug, and Cosmetic Act. Most such products fall into the moderate-risk device class and reach the market through the premarket notification pathway, requiring the manufacturer to demonstrate substantial equivalence to a legally marketed predicate. Higher-risk or novel algorithms may instead require premarket approval or use the De Novo classification route. Suppliers must also comply with the Quality System Regulation covering design controls and manufacturing, register their establishment, list the device, and meet post-market surveillance obligations, including reporting adverse events tied to algorithm performance drift.

Competition in the United States runs between the suppliers this study tracks: Agfa Healthcare, Ada Health GmbH, Arterys, Bay Labs, Inc. (Caption Health Inc.), Babylon, BenevolentAI, Butterfly Network, Inc., EchoNous, Inc., Enlitic, Inc., Gauss Surgical, GE Healthcare, IBM Corporation, Lunit Inc., Microsoft Corporation, NVIDIA Corporation, Philips Healthcare, OrCam, ai, Siemens Healthineers AG and Zebra Medical Vision. The commercially relevant division is 32% of 2025 revenue in CT Scanners, where the volume is, against 35.8% growth in Optical Coherence Tomography Devices, where share moves. Country-level positioning and shares for each of these companies are part of the full report, not of this summary.

Canada is sized at USD 0.125 billion in 2025, rising to USD 1.116 billion by 2034; 6.76% of global revenue and 15% of North America. It is reported separately from the United States across every segmentation axis in the full report.

24% of the global ai in medical imaging market sits in Europe in 2025, worth USD 0.444 billion on the way to USD 4.308 billion by 2034. It is a leading region on this axis, second by revenue throughout the period.

Share settles at 22% in 2034, while nothing contracts here; other regions simply grow faster, which shows up as relative weight, not as falling revenue.

Segment composition follows the global pattern: CT Scanners largest at 32% of 2025 revenue, Optical Coherence Tomography Devices fastest at 35.8%. Revenue for Europe is broken out by every segmentation axis and by country in the full report.

The largest single market in Europe is Germany, at USD 0.133 billion in 2025 and USD 1.292 billion in 2034. At 30% of the region in 2025 it leads, but a majority of Europe's revenue is generated in other markets. Regional revenue of USD 0.444 billion in 2025 and USD 4.308 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Demand in Germany follows the product mix reported at global level: CT Scanners is the largest line at 32% of 2025 revenue, moving to 28% by 2034, while Optical Coherence Tomography Devices grows fastest at 35.8% and takes its share from 8% to 12%. With 30% of Europe concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Germany carries its own product breakdown in the full report.

In Germany, AI-based medical imaging devices are governed by the EU Medical Device Regulation, enforced domestically through the Medical Devices Act and overseen by the Federal Institute for Drugs and Medical Devices alongside notified bodies that assess conformity. Most imaging algorithms qualify as moderate to higher-risk devices requiring a notified body to review technical documentation, clinical evaluation, and a quality management system before a CE mark can be affixed. Manufacturers must also satisfy standards governing software lifecycle processes and risk management, maintain post-market surveillance, and report incidents to the competent authority. Continued market access stays contingent on sustained conformity across updates to the underlying algorithm.

Agfa Healthcare, Ada Health GmbH, Arterys, Bay Labs, Inc. (Caption Health Inc.), Babylon, BenevolentAI, Butterfly Network, Inc., EchoNous, Inc., Enlitic, Inc., Gauss Surgical, GE Healthcare, IBM Corporation, Lunit Inc., Microsoft Corporation, NVIDIA Corporation, Philips Healthcare, OrCam, ai, Siemens Healthineers AG and Zebra Medical Vision are the suppliers covered in Germany. CT Scanners, at 32% of 2025 revenue, is where the volume sits, and Optical Coherence Tomography Devices, growing at 35.8%, is where position changes hands over the forecast period. A supplier weighted toward Europe is competing over a base of USD 0.444 billion in 2025 reaching USD 4.308 billion by 2034, 24% of global revenue at the start of that period.

The United Kingdom is sized at USD 0.111 billion in 2025, rising to USD 1.077 billion by 2034; 6% of global revenue and 25% of Europe. It is reported separately from Germany across every segmentation axis in the full report.

Within Europe, France accounts for 18% of regional revenue and 4.32% of the global total, worth USD 0.08 billion in 2025 and USD 0.775 billion by 2034.

Asia Pacific holds 22% of the global ai in medical imaging market in 2025, worth USD 0.407 billion on the way to USD 5.874 billion by 2034. That makes it the third-largest region covered, in 2025 and again in 2034.

Its share rises to 30% over the forecast period, because it outgrows the market's 30%; the revenue added here is disproportionate to where the region started.

Within the region the product split tracks the global one; 32% of 2025 revenue in CT Scanners, fastest growth of 35.8% in Optical Coherence Tomography Devices. The full report breaks Asia Pacific out along every axis and by country.

35% of Asia Pacific's base-year revenue comes from China; USD 0.142 billion, rising to USD 2.056 billion by 2034. Its 35% of base-year regional revenue leads the region, though enough sits elsewhere that Asia Pacific is not a proxy for it. Set against USD 0.407 billion and USD 5.874 billion for the region, it is why this market, and not a smaller one, is the one reported in full.

China buys along the same lines as the market globally; CT Scanners first at 32% of 2025 revenue and 28% in 2034, Optical Coherence Tomography Devices fastest at 35.8% on a share moving from 8% to 12%. Its 35% weight in Asia Pacific means those movements carry straight into the regional totals. China carries its own product breakdown in the full report.

In China, AI-enabled medical imaging software is regulated by the National Medical Products Administration, which classifies such products according to their diagnostic risk and intended use. Algorithms intended to assist or automate diagnosis typically require registration as a higher-risk medical device, involving clinical evaluation, technical review, and factory inspection before approval is granted. The regulator has issued dedicated guidance for AI-based software as a medical device, addressing training data provenance, version updates, and continued learning, and requiring manufacturers to seek supplementary approval when an update meaningfully changes diagnostic performance. Labelling must appear in Chinese and specify the approved clinical scope of use.

Agfa Healthcare, Ada Health GmbH, Arterys, Bay Labs, Inc. (Caption Health Inc.), Babylon, BenevolentAI, Butterfly Network, Inc., EchoNous, Inc., Enlitic, Inc., Gauss Surgical, GE Healthcare, IBM Corporation, Lunit Inc., Microsoft Corporation, NVIDIA Corporation, Philips Healthcare, OrCam, ai, Siemens Healthineers AG and Zebra Medical Vision are the suppliers covered in China. Two different problems sit on the same axis: holding CT Scanners at 32% of 2025 revenue, and taking Optical Coherence Tomography Devices while it grows at 35.8%. Weighting toward Asia Pacific means competing for 22% of 2025 global revenue, a base of USD 0.407 billion moving to USD 5.874 billion across the forecast period.

Japan is sized at USD 0.09 billion in 2025, rising to USD 1.292 billion by 2034; 4.86% of global revenue and 22% of Asia Pacific. It is reported separately from China across every segmentation axis in the full report.

Within Asia Pacific, India accounts for 15% of regional revenue and 3.3% of the global total, worth USD 0.061 billion in 2025 and USD 0.881 billion by 2034.

Latin America holds 5% of the global ai in medical imaging market in 2025, worth USD 0.093 billion on the way to USD 1.175 billion by 2034. It is a marginal region on this axis, fourth by revenue throughout the period.

6% of global revenue sits here by 2034, up from the 2025 level, at a pace above the 30% global rate, so this region warrants separate treatment and should not be scaled off the total.

Within the region the product split tracks the global one; 32% of 2025 revenue in CT Scanners, fastest growth of 35.8% in Optical Coherence Tomography Devices. Revenue for Latin America is broken out by every segmentation axis and by country in the full report.

USD 0.051 billion of Latin America's 2025 revenue is generated in Brazil, the region's largest market, reaching USD 0.646 billion by 2034. At 55% of the region in 2025 it leads, but a majority of Latin America's revenue is generated in other markets. Against regional totals of USD 0.093 billion in 2025 and USD 1.175 billion in 2034, it is the country the full report breaks out in detail.

Demand in Brazil follows the product mix reported at global level: CT Scanners is the largest line at 32% of 2025 revenue, moving to 28% by 2034, while Optical Coherence Tomography Devices grows fastest at 35.8% and takes its share from 8% to 12%. Because the country carries 55% of Latin America, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Brazil carries its own product breakdown in the full report.

In Brazil, medical imaging software that incorporates artificial intelligence falls under the oversight of the National Health Surveillance Agency, which treats such products as medical devices subject to registration before sale. Classification depends on the clinical risk posed by the software's intended use, with diagnostic-support tools generally requiring a fuller technical dossier covering safety, performance, and clinical evidence than lower-risk administrative tools. Manufacturers must demonstrate conformity with the agency's quality management requirements, often aligned with recognized international standards for medical device software, and must maintain a local technical representative. Post-market obligations include vigilance reporting and re-registration whenever the software undergoes a substantive change.

Agfa Healthcare, Ada Health GmbH, Arterys, Bay Labs, Inc. (Caption Health Inc.), Babylon, BenevolentAI, Butterfly Network, Inc., EchoNous, Inc., Enlitic, Inc., Gauss Surgical, GE Healthcare, IBM Corporation, Lunit Inc., Microsoft Corporation, NVIDIA Corporation, Philips Healthcare, OrCam, ai, Siemens Healthineers AG and Zebra Medical Vision are the suppliers covered in Brazil. Two different problems sit on the same axis: holding CT Scanners at 32% of 2025 revenue, and taking Optical Coherence Tomography Devices while it grows at 35.8%. A supplier weighted toward Latin America is competing over a base of USD 0.093 billion in 2025 reaching USD 1.175 billion by 2034, 5% of global revenue at the start of that period.

Mexico is sized at USD 0.028 billion in 2025, rising to USD 0.353 billion by 2034; 1.51% of global revenue and 30% of Latin America. It is reported separately from Brazil across every segmentation axis in the full report.

USD 0.073 billion of 2025 revenue is generated in Middle East and Africa, 4% of the global ai in medical imaging market with USD 0.783 billion projected for 2034. That makes it the fifth-largest region covered, in 2025 and again in 2034.

Its share moves to 4% by 2034, while nothing contracts here; other regions simply grow faster, which shows up as relative weight, not as falling revenue.

The product mix reported at global level applies here, with CT Scanners the largest line at 32% of 2025 revenue and Optical Coherence Tomography Devices the fastest-growing at 35.8%. Middle East and Africa is reported axis by axis and country by country in the full study.

The largest single market in Middle East and Africa is Saudi Arabia, at USD 0.026 billion in 2025 and USD 0.274 billion in 2034. 35% of the region in the base year makes it the largest market here without making it the region. The region itself runs USD 0.073 billion to USD 0.783 billion over the same period, and this is the market carrying the country-level detail in the full report.

Demand in Saudi Arabia follows the product mix reported at global level: CT Scanners is the largest line at 32% of 2025 revenue, moving to 28% by 2034, while Optical Coherence Tomography Devices grows fastest at 35.8% and takes its share from 8% to 12%. Because the country carries 35% of Middle East and Africa, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Saudi Arabia carries its own product breakdown in the full report.

In Saudi Arabia, AI-driven medical imaging products are regulated by the Saudi Food and Drug Authority, which requires registration of medical device software before it can be marketed or used in a clinical setting. The authority applies a risk-based classification broadly aligned with international frameworks, so imaging algorithms used for diagnostic support generally sit in a higher-risk category demanding fuller technical and clinical documentation. Suppliers must show conformity with recognized software lifecycle and risk-management standards, appoint a local authorized representative, and secure marketing authorization prior to distribution. Ongoing compliance includes reporting adverse events and notifying the authority of material changes to the algorithm's function or intended use.

Competition in Saudi Arabia runs between the suppliers this study tracks: Agfa Healthcare, Ada Health GmbH, Arterys, Bay Labs, Inc. (Caption Health Inc.), Babylon, BenevolentAI, Butterfly Network, Inc., EchoNous, Inc., Enlitic, Inc., Gauss Surgical, GE Healthcare, IBM Corporation, Lunit Inc., Microsoft Corporation, NVIDIA Corporation, Philips Healthcare, OrCam, ai, Siemens Healthineers AG and Zebra Medical Vision. Two different problems sit on the same axis: holding CT Scanners at 32% of 2025 revenue, and taking Optical Coherence Tomography Devices while it grows at 35.8%. Weighting toward Middle East and Africa means competing for 4% of 2025 global revenue, a base of USD 0.073 billion moving to USD 0.783 billion across the forecast period.

1.19% of global revenue is generated in the United Arab Emirates; USD 0.022 billion in 2025, reaching USD 0.235 billion in 2034, and 30% of Middle East and Africa.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by Product, End Use, Application, AI Technology, Component, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.